首页 | 本学科首页   官方微博 | 高级检索  
检索        

沙利度胺与二丁酰环磷腺苷钙治疗老年重度寻常型银屑病的药物经济学评价
引用本文:杨月,张志勤,张黎哲.沙利度胺与二丁酰环磷腺苷钙治疗老年重度寻常型银屑病的药物经济学评价[J].中国现代应用药学,2020,37(11):1380-1384.
作者姓名:杨月  张志勤  张黎哲
作者单位:大连市皮肤病医院
摘    要:目的 对沙利度胺与二丁酰环磷腺苷钙治疗老年重度寻常型银屑病进行药物经济学评价。 方法 通过医院信息系统(HIS)采集2016年10月1日到2018年5月31日在大连市皮肤病医院老年重度寻常型银屑病患者的病历资料进行回顾性分析,比较接受沙利度胺与二丁酰环磷腺苷钙治疗老年重度寻常型银屑病的疗效和成本费用,并采用单因素敏感性分析结果的稳定性。 结果 沙利度胺组显效率为43.37%,二丁酰环磷腺苷钙组显效率为35.00%,应用χ2检验比较无统计学差异(P>0.05);沙利度胺组3、6个月未再次入院风险率为86.75%和71.08%,二丁酰环磷腺苷钙组3、6个月未再次入院风险率为75.00%和57.00%,应用χ2检验比较有统计学差异(P<0.05);沙利度胺组人均成本9999.86元,二丁酰环磷腺苷钙组人均成本9223.17元;以显效率为疗效指标二丁酰环磷腺苷钙成本最低,以3、6个月未再次入院风险率为疗效指标沙利度胺具有最优经济性(ICER=6472.42/5547.79元),敏感性分析显示结果可靠。 结论 二丁酰环磷腺苷钙治疗老年重度寻常型银屑病近期疗效成本最低,而沙利度胺的远期疗效更具有成本效果优势。

关 键 词:沙利度胺  二丁酰环磷腺苷钙  寻常型银屑病  最小成本分析  成本-效果
收稿时间:2019/7/19 0:00:00
修稿时间:2020/6/5 0:00:00

Pharmacoeconmic Evaluation of Thalidomide and Calcium Dibutyryladenosine Cyclophosphate in the Treatment of Elderly Severe Psoriasis Vulgaris
YANG Yue,ZHANG Zhiqin,ZHANG Lizhe.Pharmacoeconmic Evaluation of Thalidomide and Calcium Dibutyryladenosine Cyclophosphate in the Treatment of Elderly Severe Psoriasis Vulgaris[J].The Chinese Journal of Modern Applied Pharmacy,2020,37(11):1380-1384.
Authors:YANG Yue  ZHANG Zhiqin  ZHANG Lizhe
Institution:Dalian Dermatosis Hospital
Abstract:Objective To compare the pharmacoeconmic of thalidomide and calcium dibutyryladenosine cyclophosphate in the treatment of elderly severe psoriasis vulgaris. Method The case data of patients with elderly severe psoriasis vulgaris in Dalian Dermatosis Hospital from October 1, 2016 to May 31, 2018 were collected through the HIS for a retrospective analysis, to compare the curative effects and costs of patients respectively accepting thalidomide and calcium dibutyryladenosine cyclophosphate to treat the elderly severe psoriasis vulgaris, and then the single factor sensitivity analysis was conducted to check the stability of results. Results The efficiencies of the group of patients treated with calcium dibutyryladenosine cyclophosphate and thalidomide had no statistical difference(43.37% vs 35%) , but the readmissions within 3 and 6 months of the THD group were significantly lower than those of the CDC group. The total cost of treatment of the THD group was 9999.86 yuan, and that of the CDC group was 9223.17 yuan. If taking the cost minimization analysis method and with marked effective rate as the index, the CDC group had better cost minimization; with the ratio of no recurrence within 3 months and 6 months as the index, the THD group had the ICER of 6472.42 yuan and 5547.79 yuan respectively compared to the CDC group, so that the increased cost was totally worthy and the THD group had the optimum economy.. Conclusion In terms of short term curative effect, the cost of CDC is lower in the treatment of elderly severe psoriasis vulgaris, while the THD enjoys cost-effectiveness advantage in long term curative effect.
Keywords:Thalidomide  Calcium dibutyryladenosine cyclophosphate  Psoriasis  Cost minimization analysis  Cost-effectiveness
点击此处可从《中国现代应用药学》浏览原始摘要信息
点击此处可从《中国现代应用药学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号